Macular Degeneration Trial, Recruiting (NCT04591483)

Macular Degeneration Trial, Recruiting NCT04591483 Sponsor: National Eye Institute (NEI) Condition: Macular Degeneration

Printed from Voxsanity (voxsanity.com.au) — NCT04591483 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Macular Degeneration

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are willing to follow all study procedures and are available for the full duration of the trial.
People who are at least 10 years old.
People who are able to complete the required vision and eye imaging tests.
People who have a mutation in the ELOVL4 gene and show typical signs of a condition called Stargardt-like macular dystrophy (an inherited eye condition affecting central vision).
People (or their legal guardian, if applicable) who are able to understand and sign the trial's consent form.

Who may not be able to join:

People who have two or more confirmed mutations in the ABCA4 gene, or one mutation in either the RDS/peripherin or PROM1 genes.
People who have certain serious health conditions throughout the body that are rarely linked to the ELOVL4 gene mutation, such as a condition called Spinocerebellar Ataxia-34 (a condition affecting movement and coordination) (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Brett G Jeffrey, Ph.D., National Eye Institute (NEI)

Phone: (301) 451-1621

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04591483

Sponsor: National Eye Institute (NEI)

Phase: Not Applicable

Status: Recruiting

Condition: Macular Degeneration

Trial contact: (301) 451-1621

More information: https://clinicaltrials.gov/study/NCT04591483

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are willing to follow all study procedures and are available for the full duration of the trial.
People who are at least 10 years old.
People who are able to complete the required vision and eye imaging tests.
People who have a mutation in the ELOVL4 gene and show typical signs of a condition called Stargardt-like macular dystrophy (an inherited eye condition affecting central vision).
People (or their legal guardian, if applicable) who are able to understand and sign the trial's consent form.

Who may not be able to join:

People who have two or more confirmed mutations in the ABCA4 gene, or one mutation in either the RDS/peripherin or PROM1 genes.
People who have certain serious health conditions throughout the body that are rarely linked to the ELOVL4 gene mutation, such as a condition called Spinocerebellar Ataxia-34 (a condition affecting movement and coordination) (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

National Eye Institute (NEI)

Registry

ClinicalTrials.gov

Start date

19 April 2022

Est. completion

16 July 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Growth rate in square root area of loss of the inner segment/outer segment band (EZband); Growth rate of square root area of atrophy measured from short-wavelength autofluorescence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov